<DOC>
	<DOCNO>NCT00795678</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop dividing . Lapatinib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Studying sample tumor tissue blood patient may help doctor understand well drug carry brain . PURPOSE : More definitive knowledge penetration chemotherapeutic agent brain necessary future rational design drug drug regimens target brain metastasis . This clinical trial study well capecitabine , cyclophosphamide , doxorubicin , gemcitabine , lapatinib , paclitaxel , trastuzumab , vinorelbine penetrates brain tumor .</brief_summary>
	<brief_title>Chemotherapeutic Agents Brain/Breast</brief_title>
	<detailed_description>OBJECTIVES : - To determine concentration capecitabine , cyclophosphamide , doxorubicin hydrochloride , gemcitabine hydrochloride , lapatinib ditosylate , paclitaxel , trastuzumab ( Herceptin® ) , vinorelbine ditartrate brain metastasis woman breast cancer . - To analyze drug penetrability model relationship drug concentration tumor drug concentration blood sample . OUTLINE : Patients assign receive 1 8 agent patient 's treating oncologist . Patients receive single dose follow study drug immediately precede surgery : oral capecitabine ; cyclophosphamide IV 30 minute ; doxorubicin hydrochloride IV 15 minute ; gemcitabine hydrochloride IV 30 minute ; oral lapatinib ditosylate* ; paclitaxel IV 3 hour ; trastuzumab ( Herceptin® ) IV 30-90 minute ; vinorelbine ditartrate IV 10-30 minute . Patients undergo craniotomy resection brain metastasis . NOTE : *Patients receive oral lapatinib ditosylate least 3 day prior surgery immediately surgery . All patient receive cyclophosphamide , doxorubicin hydrochloride , gemcitabine hydrochloride , paclitaxel , vinorelbine ditartrate also receive single dose pegfilgrastim subcutaneously ( SC ) 24-48 hour study drug administration OR filgrastim ( G-CSF ) SC daily 10 day , begin 24-48 hour study drug administration . Blood sample collect periodically pharmacological study . Tissue sample obtain surgical resection blood sample use establish cell line analyze drug concentration HPLC , LC-MS/MS ELISA .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast carcinoma ≥ 1 suspect know parenchymal brain metastasis surgical resection biopsy clinically indicate Treating oncologist must agree patient would derive clinical benefit receive ≥ 1 follow study agent : Capecitabine , cyclophosphamide , doxorubicin hydrochloride , gemcitabine hydrochloride , lapatinib ditosylate , paclitaxel , trastuzumab ( Herceptin® ) , vinorelbine ditartrate Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify Karnofsky performance status 50100 % Life expectancy ≥ 3 month Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ( total ) ≤ 1.5 time ULN AST ≤ 3 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception three month completion study treatment No severe NYHA class IIIIV cardiac insufficiency uncontrolled and/or unstable cardiac coronary artery disease No history noncompliance medical regimen inability unwillingness return schedule visit PRIOR CONCURRENT THERAPY : No toxicity &gt; grade 2 prior chemotherapy radiotherapy remain time study entry At least 60 day since prior bevacizumab At least 4 week since prior cranial radiotherapy At least 3 week since prior cytotoxic chemotherapy ( 6 week nitrosoureas mitomycin C ) At least 2 week since prior noncytotoxic drug ( e.g. , small moleculetargeted drug ) No concurrent experimental therapy Concurrent hormone therapy and/or trastuzumab ( Herceptin® ) allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>tumor metastatic brain</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>